Very efficient myoblast allotransplantation in mice under FK506 immunosuppression

Muscle & Nerve
I KinoshitaJ P Tremblay

Abstract

Transgenic CD1 mice expressing beta-galactosidase were used as myoblast donors. The myoblasts were injected in normal or mdx muscles previously irradiated and injected with notexin. Twenty-eight days after myoblast transplantation, the percentage of muscle fibers beta-glactosidase-positive was low in mice not immunosuppressed but was high (80%) in those treated with FK506. In mdx mice, muscle fibers expressing beta-galactosidase were also dystrophin positive. Most of the mice not treated with FK506 produced antibodies against the donor myoblasts. These results indicate that FK506 is a very useful immunosuppressive drug for myoblast transplantation in mice. Irradiation and notexin injection used in our experiments are, however, not feasible in humans. Other manipulations capable of increasing the participation of donor myoblasts to regeneration will therefore have to be identified before new clinical trials are attempted.

References

May 1, 1992·Muscle & Nerve·J HuardJ P Tremblay
Apr 1, 1993·Journal of the Neurological Sciences·J E MorganT A Partridge
Feb 1, 1994·The Journal of Clinical Investigation·J HuardJ P Tremblay
Oct 1, 1993·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A SatohJ P Tremblay
Jul 1, 1993·Annals of Neurology·G KarpatiM Vanasse

❮ Previous
Next ❯

Citations

Feb 1, 1996·Muscle & Nerve·J E MorganT A Partridge
Jul 1, 1996·Muscle & Nerve·Y FanM Grounds
Sep 28, 2010·Surgery Today·Beniamino Palmieri, Jacques P Tremblay
Nov 1, 1995·Neuromuscular Disorders : NMD·J T VilquinJ P Tremblay
May 1, 1996·Neuromuscular Disorders : NMD·I KinoshitaJ P Tremblay
Mar 17, 2004·Toxicon : Official Journal of the International Society on Toxinology·J B Harris
Aug 28, 2001·Journal of Biotechnology·P BoudreaultA Garnier
Dec 12, 2001·Neuromuscular Disorders : NMD·K Leriche-GuérinJ P Tremblay
Jun 3, 1998·Neuromuscular Disorders : NMD·H ItoJ P Tremblay
Jun 19, 1998·Neuromuscular Disorders : NMD·J C van DeutekomJ Huard
Jul 1, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jacques P TremblayDavid M Rothstein
Jul 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bridget M DeasyJohnny Huard
Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christophe PichavantJacques P Tremblay
Jan 5, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jacques P TremblayRobert Frederickson
Feb 4, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xiaoyin XuYaming Wang
Feb 27, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Cyril CatelainJean-Thomas Vilquin
Mar 28, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bruno PéaultJohnny Huard
Aug 30, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Madoka IkemotoShin'ichi Takeda
Sep 28, 1995·The New England Journal of Medicine·J R MendellR Rice
May 18, 2013·Tissue Engineering. Part B, Reviews·Jonathan Mark FishmanPaolo De Coppi
Oct 22, 2003·Current Opinion in Rheumatology·Daniel Skuk, Jacques P Tremblay
Jun 2, 2000·Biochemical and Biophysical Research Communications·S Seigneurin-VeninJ P Tremblay
Jul 24, 2014·BioMed Research International·Sara Martina MaffiolettiFrancesco Saverio Tedesco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.